GUTS FRACTYL HEALTH INC

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2024 and provide business updates after market close on Monday, May 13, 2024. The Company’s management will host a conference call on the same day beginning at 4:30 p.m. ET.

A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website at . The webcast will be archived and available for replay following the live event.

About Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit  or .

Contacts 

Corporate Contact 

Lisa Davidson, Chief Financial Officer 

, 781.902.8800

Media Contact 

Beth Brett, Corporate Communications 

, 720.656.6544

Investor Contact

Stephen Jasper Gilmartin Group

, 619.949.3681



EN
07/05/2024

Underlying

GUTSFRACTYL HEALTH INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FRACTYL HEALTH INC

 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Reports First Quarter 2024 Financial Results and Provid...

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1 pivotal study in patients with inadequately controlled T2D anticipated in the fourth quarter 2024 Update from real-world Germany registry study of Revita in patients with T2D at DDG Annual Meeting Appointed Adrian Kimber as Chief Commercial Officer to lead Revita launch readiness activities Conference call ...

May 13, 2024 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Presents Clinical Update on Revita® German Real-World R...

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single Revita treatment No device- or procedure-related serious adverse events have been observed to date in any registry participant BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focuse...

May 13, 2024 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health to Present at BofA Securities 2024 Health Care Conferen...

Fractyl Health to Present at BofA Securities 2024 Health Care Conference BURLINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, will participate in a fireside chat at the upcoming BofA Securities 2024 Health Care Conference on Wednesday, May 15, 2024, at 4:20 p.m. PDT (7:20 p.m. EDT). To register in advance for the fireside chat webcast, sign up . ...

May 8, 2024 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health to Report First Quarter 2024 Financial Results and Prov...

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2024 and provide business updates after market close on Monday, May 13, 2024. The Company’s management will host a conference call on the same day beginning at 4:30 p.m. ET. A live webc...

May 7, 2024 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Announces Multiple Presentations at the Upcoming Digest...

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita® in patients with T2D in Germany At DDW, Fractyl Health will provide an oral presentation from its Rejuva® platform with new preclinical data demonstrating the potential of GLP-1 based pancreatic gene therapy (GLP-1 PGTx) to durably reduce liver fat in the diet-induced obesity model BURLINGTON, Mass., April 30, 202...

April 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch